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http://www.translational-medicine.com/content/12/1/279RESEARCH Open AccessPropofol exerts anti-hepatocellular carcinoma by
microvesicle-mediated transfer of miR-142-3p
from macrophage to cancer cells
Jian Zhang1†, Wei-feng Shan1†, Te-te Jin1, Guo-qing Wu2, Xiao-xing Xiong1, Hai-yan Jin3 and Sheng-mei Zhu1*Abstract
Objective: We previously confirmed that propofol directly inhibited the viability, proliferation, and invasiveness of
hepatocellular carcinoma cells in vitro. In this study, we investigated the mechanism underlying the anti-HCC effects
of propofol.
Methods: In vivo antitumor activity was investigated in tumor-bearing mice following an intraperitoneal injection
of propofol, with or without clodrolip. The co-culture system was used to verify that miR-142-3p was transported
from macrophages to HCC cells. A miR-142-3p inhibitor was used to down-regulate the expression of miR-142-3p.
Results: Propofol drastically inhibited tumor growth in tomor-bearing mice through macrophage activation, and
stimulated tumor-associated macrophages (TAMs) to secrete microvesicles (MVs), which delivered miR-142-3p to
HCC cells, resulting in the inhibition of HCC cell invasion. In addition, MVs collected from the plasma of the
tumor-bearing mice injected with propofol suppressed tumor growth. More importantly, down-regulation of the
expression miR-142-3p reversed the effect of propofol on HCC cell migration.
Conclusions: This study reveals a novel role for propofol in the inhibition of HCC through MV-mediated transfer
of miR-142-3p from macrophages to cancer cells in vivo.
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Hepatocellular carcinoma (HCC), a primary malignant
tumor, has a poor prognosis and is the third cause of
tumor-related deaths in China [1,2]. Although multiple
treatment strategies, including surgical resection, liver
transplantation, systemic or infusional chemotherapy,
and targeted immunotherapy, have been applied, the
overall 5-year survival rate for patients with HCC is still
low [3,4]. Due to malignant proliferation and metastasis,
there is no treatment to improve the survival of patients
with advanced HCC [5,6]. Therefore, it is urgent to es-
tablish novel anticancer reagents to prevent the invasive-
ness of HCC.* Correspondence: smzhu20088@163.com
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unless otherwise stated.Propofol (2, 6-diisopropylphenol), an intravenous
anesthetic, also has antitumor effects [7,8]. Clinically
relevant concentrations of propofol can induce apoptosis
and inhibit the invasion of human cancer cells [9]. For ex-
ample, propofol treatment resulted in the apoptosis of hu-
man promyelocytic leukemia cells [10]. It also significantly
decreased the invasive activity of human colon carcinoma
cells [11]. In animal studies, propofol appeared to exert
antitumor activity by modulation of the immune reaction
[12]. Our previous study showed that propofol directly
inhibited the viability, proliferation, and invasiveness of
HCC cells in vitro [13,14]. However, it is unclear whether
propofol has a therapeutic effect on HCC in vivo.
The role for microRNAs (miRNAs) in carcinogenesis,
development and progression of HCC has been well
established. Some miRNAs such as miR-122, miR-199
family and MiR-124 is downregulated in HCC and act
as putative tumor suppressor genes [15]. Furthermore,
overexpression of these miRNAs could induce apoptosisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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contrary, miR-21, miR-221/mir-222 and MiR-224 may
act as oncogenes in support of the tumor-promoting ac-
tivity [17]. In addition, several miRNAs are involved in
regulation of the invasive and/or metastatic potential of
HCC [18]. Wu et al. has demonstrated that miR-142-3p
plays an important role in inhibiting migration and inva-
sion of HCC cells [19]. More importantly, miR-142-3p
exerts anti-tumor effect by regulation of the differenti-
ation of macrophages [20]. Thus, modulation of miR-
142-3p expression and activity may be a novel approach
to HCC therapy.
Microvesicles (MVs), also known as exosomes, are
derived from multivesicular endosomes that mediate cell-
to-cell communication [21]. Increasing evidence indicated
that MVs can shuttle miRNAs into neighboring or distant
cells and regulate target gene expression [22]. Yang et al.
demonstrated that MVs released from macrophage can
transfer miR-123 to breast cancer cells which resulted in
promoting metastasis of cancer cells [23]. Therefore, se-
creted miRNAs may serve as novel therapeutic targets for
treatment of cancer. In the present study, we have investi-
gated the effect of propofol on anti-HCC in vivo, and




RPMI 1640 was obtained from GIBCO (Invitrogen,
Carlsbad, CA, USA). Fetal bovine serum (FBS) was ob-
tained from Hyclone (Logan, UT, USA). Lipofectamine
2000 transfection reagent was obtained from Invitrogen
Life Technologies (Grand Island, NY, USA). Propofol was
purchased from Sigma Aldrich (St Louis, MO, USA). A
cholesterol-conjugated miR-142-3p inhibitor and a nega-
tive control (Nc) oligonucleotide for in vivo RNA delivery
were purchased from RiboBio (Guangzhou, China). Anti-
bodies against RAC1 and GAPDH were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). A
detergent-compatible protein assay kit was purchased from
Bio-Rad Laboratories (Hercules, CA, USA). An miRNeasy
Mini kit, miScript Reverse Transcription kit, and miScript
SYBR Green PCR kit were purchased from Qiagen
(Hilden, Germany). Clodronate encapsulated in liposome
nanoparticles (5 mg/ml) was purchased from Encapsula
Nanosciences Inc.
Cell culture
A mouse HCC cell line, Hepa1-6, and a mouse macro-
phage cell line, Raw 264.7, were obtained from the
Chinese Academy of Sciences (Shanghai, China). The cells
were cultured in complete RPMI 1640 with 10% FBS and
treated with propofol (dissolved in RPMI 1640) in
complete medium. To obtain reliable results, the finalconcentration of RPMI 1640 in the culture medium was
less than 0.1%.
Animal tumor model
All the experiments were approved by the Experimental
Animal Ethics Committee of Zhejiang University and
performed under the guidelines of the Institutional Animal
Care and Use Committee. Male C57L/J 8-week-old
mice were purchased from Shanghai Laboratory Animal
Centre (Chinese Academy of Sciences). Hepa1-6 cells
(5 × 106 cells) were injected into the right flank of the
C57L/J mice for 5 days. The mice were then randomly
divided and assigned to the following treatments (n = 8
in each group): 20 mg/kg of propofol, 100 μg/kg of clo-
drolip, 20 mg/kg of propofol + 100 μg/kg of clodrolip,
50 mg/kg of propofol, 50 mg/kg of propofol + 100 μg/kg
of clodrolip, 20 μg of MVs, the miR-142-3p inhibitor, or
20 mg/kg of propofol + the miR-142-3p inhibitor. Propo-
fol in 0.5 ml of soybean oil was administered by intra-
peritoneal (i.p.) injection once a day for 3 weeks. For
macrophage depletion, 100 μl of clodronate liposomes
were injected via the i.p. route into the tumor-bearing
mice weekly. The Nc and the miR-142-3p inhibitor
(10 nmol) in 0.1 ml of saline buffer were administered
intratumorally every 2 days for 3 weeks. Tumor growth
was assessed twice a week with a caliper measurement,
and the volume (V) was calculated using the formula
V = 1/2 × length × (width)2.
Preparation and culture of mouse tumor-associated
macrophages
Tumor-associated macrophages (TAMs) were isolated
from the tumors according to previous report [24].
Briefly, small pieces of solid tumors tissue was digested
with0.125% (wt/vol) Trypsin (Sigma) for 40 minutes at
37°C, followed by washing twice in incomplete RPMI
1640 medium. Cells were seeded in dishes of RPMI 1640
medium with 10% FBS and, after 12 h of incubation,
non-adherent cells were vigorously washed off. The ad-
herent cells were greater than 95% macrophages.
Isolation of MVs by differential centrifugation
The MVs were isolated from the cell culture medium
by differential centrifugation according to the method
described in a previous report [21]. The cells and cell
debris were removed by centrifugation at 300 × g for
10 min, 1200 × g for 10 min, and 10000 × g for 30 min.
Supernatant was sequentially centrifuged at 11,0000 × g
for 2 h (all steps were performed at 4°C). The MVs were
collected from the pellet and resuspended in phosphate
buffer saline (PBS) buffer. The total protein content in
the MVs was measured, and the levels of MVs were de-
termined by measuring the total protein content, which
is presented as micrograms of total protein in the MVs.
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overexpressing RAC1
The full-length coding sequence for mouse RAC1 was
amplified by PCR from the mouse full-length cDNA based
on GeneBank sequences. DNA encoding the RAC1 was
subcloned from pCMV3.0b-myc-RAC1 into pAdTrack-
CMV. All the sequences were confirmed by automated
DNA sequencing. These shuttle plasmids were then
recombined with the backbone vector pAdEasy-1 in
BJ5183 bacteria. Viral particles were purified using the
Virabind™ Adenovirus Purification Kit (Cell Biolabs, Inc.,
San Diego, CA, USA). Raw 264.7 cells were infected with
adenovirus at an MOI of 100 at 37°C for 2 h. The cells
were then cultured in fresh medium for 24 h or 48 h.
Oligonucleotides and Cell Transfection
Hepa1-6 and Raw 264.7 cells were seeded in 6-well or
24-well plates and transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. For the knockdown of miR-142-
3p, miR-142-3p inhibitor or a negative-control (Nc) was
used at the concentration of 100 nM. The cells were
treated with propofol after the transfection for 24 h.
Quantitative real-time PCR (Q-PCR) analysis
Approximately 5 × 106 cells were treated with or without
(control) propofol for 24 h. Mature miRNAs were iso-
lated and purified using Trizol reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s
protocol. The levels of miR-142-3p, miR-199a, miR-
122, and miR-29 were quantified with a TaqMan PCR
kit. Real-time PCR was performed with LightCycler
480, using U6 small nuclear RNA as an internal normal-
ized reference.
The expression of mRNA was measured using SYBR
GREEN PCR Master Mix (Applied Biosystems). The
specific primers were as follows: RAC1, 5′-TTGCC
AAAATACCTTCTGAACT-3′ (forward) and 5′-TGCTT
TACGCATCTGAGAACTA-3′ (reverse); GAPDH, 5′-TG
AAGCAGGCA TCTGAGGG-3′ (forward) and 5′-CGAA
GGTGGAAGAGTGGGAG-3′ (reverse). All data were
analyzed using GAPDH gene expression as an internal
standard.
Tumor invasion assay
The tumor invasion assay used modified Boyden cham-
bers (8-μm pore size, BD Biosciences, USA), in which
the various cellular components were grown without
direct cell-to-cell contact. Briefly, the membrane was
coated with Matrigel (BD) diluted 1/5 in serum-free
DMEM media on ice. Hepa1-6 cells (1 × 105 cells) were
seeded in the upper well of the chamber, and the lower
well was filled with TAMs. After co-culture for 24 h, the
transwells were removed from the 24-well plates, andthe non-invaded cells were scraped off the top of the
Transwell filters with a cotton swab. The filter was fixed
formaldehyde (4%) and stained with 0.1% crystal violet
in 2% methanol. Invasiveness was determined by count-
ing cells in five microscopic fields per well, and the ex-
tent of invasion was expressed as an average number of
cells per microscopic field.
Statistical analysis
Statistical analysis was performed with SPSS 13.0 soft-
ware. The statistical analyses used an analysis of variance
(ANOVA) or the Student’s t-test. Data were expressed as
the mean ± standard deviation. P < 0.05 was considered
significant.
Results
Propofol inhibited HCC growth through macrophage
in vivo
Our previous study showed that propofol induced apop-
tosis and impaired the invasiveness of HCC cell lines
in vitro [14,15]. To evaluate the effects of propofol on
HCC in vivo, we examined tumor growth in tumor-
bearing mice treated with propofol. The size of the tu-
mors significantly decreased in a dose-dependent man-
ner following the i.p. injection of 20 and 50 mg/kg of
propofol (Figure 1A). The tumor-bearing mice were sacri-
ficed on Day 26 after the injection of the Hepa1-6 cells.
The mean tumor volume, which was 276.67 ± 25.17 mm3
in the control group, was dose-dependently reduced in
the propofol treatment group (183.33 ± 20.83 mm3 in the
20 mg/kg group and 103.33 ± 15.28 mm3 in the 50 mg/kg
group) (Figure 1B).
To determine whether the administration of propofol
elicited the activation of macrophages within a HCC en-
vironment, we analyzed the expression of TNF-αand
CD206 in the TAMs of the hepatoma-bearing mice
injected with different amounts of propofol. The
TAMs from the propofol-injected mice had higher
expression of TNF-α but lower expression of CD206
(Figure 1C and D).
Cocultivation with TAMs from the propofol–treated HCC
tissue increased miR-142-3p levels in HCC cells
To explore the mechanism underling the involvement
of TAMs in the antitumor activity of propofol, we
measured the expression of a number of miRNAs, includ-
ing miR-142-3p, miR-199a, miR-122, and miR-29, which
may act as tumor suppressors in HCC [23]. Hepa1-6 cells
cocultured with TAMs (1:1) from the propofol-treated
HCC tissue exhibited a dose-dependent increase in
cellular miR-142-3p levels relative to cells that were
cocultured with TAMs from soybean oil-treated HCC tis-
sue (Figure 2A). However, there was no change in the ex-
pression of miR-199a, miR-122, and miR-29 (Figure 2B).
Figure 1 Propofol inhibited HCC growth in vivo. The tumor-bearing mice were treated with 0 mg/kg, 20 mg/kg and 50 mg/kg propofol by
i.p. injection. (A)Tumor sizes on each mouse were monitored 2 times per week and (C) tumor weights were measured. The tumor-bearing mice
were treated with 100 μg/kg clodrolip, 20 mg/kg propofol + 100 μg/kg clodrolip, 50 mg/kg propofol + 100 μg/kg clodrolip, (B) Tumor sizes and
(D) tumor weights were determined. *P < 0.05, **P < 0.01 indicate significant differences from control group. #P < 0.05, ##P < 0.01 indicate significant
differences from clodrolip group.
Figure 2 Co-cultivation with TAMs from propofol–treated HCC tissue increased miR-142-3p levels in HCC cells. (A) The expression of
miR-142-3p in Hepa1-6 cells after 24 h co-culture with TAMs isolated from tumor-bearing mice treated with 0 mg/kg, 20 mg/kg and 50 mg/kg
propofol by i.p. injection. The relative mRNA (B) and protein (C) levels of RAC1 in Hepa1-6 cells after 24 h co-culture with TAMs isolated from
tumor-bearing mice treated with 0 mg/kg, 20 mg/kg and 50 mg/kg propofol by i.p. injection. **P < 0.01, indicate significant differences from
TAMs isolated from tumor-bearing mice treated with 0 mg/kg propofol.
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[25], was significantly down-regulated in the HCC cells
following incubation with TAMs from the propofol-Figure 3 Propofol stimulated miR-142-3p shuttling from macrophage
from tumor-bearing mice injected with propofol, (B) in MVs from propofol
propofol-treated TAMs. (D) Hepa1-6 cells were co-cultured with TAMs for 4
The invasion of Hepa1-6 cells was assessed by counting the cells in the ba
of miR-142-3p was determined (E) in Raw 264.7 cells treated with different
(G) Hepa1-6 cells were incubated with MVs from propofol-treated Raw 264
transfection of RAC1 expressing plasmid for 24 h, Hepa1-6 cells were treated w
Hepa1-6 cells was assessed. (I) The level of miR-142-3p was measured in Hepa1
and **P < 0.01, indicate significant differences from control.treated HCC tissue (Figure 2C and 2D), suggesting that
the level of functional miR-142-3p levels increased in
the HCC cells.s to HCC cells. The level of miR-142-3p was determined (A) in TAMs
-treated TAMs and (C) in Hepa1-6 cells treated with MVs from
8 h. Cell invasiveness was measured using a transwell invasion assay.
solateral side of the transwell filters under a light microscope. The level
concentration of propofol for 24 h and (F) in MVs from Raw 264.7 cells.
.7 cells for 48 h. The invasion of Hepa1-6 cells was assessed. (H) After
ith MVs from propofol-treated Raw 264.7 cells for 48 h. The invasion of
-6 cells treated with different concentration of propofol for 24 h. *P < 0.05
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shuttling from macrophages to HCC cells
A previous study demonstrated that miR-142-3p pre-
vents the differentiation of macrophages and inhibits
their immunosuppressive function in tumors [24]. To
determine whether propofol treatment stimulated miR-
142-3p shuttling from macrophages to the HCC cells,
we determined the expression of miR-142-3p in mac-
rophages and MVs secreted from macrophages. As
expected, the expression of miR-142-3p in the TAMs
of the tumor-bearing mice injected with propofol was
obviously increased compared with those of the soy-
bean oil-injected mice (Figure 3A). Consistent with
this observation, the level of miR-142-3p in the MVs
from the propofol-treated TAMs was also higher than
that in the soybean oil-treated mice (Figure 3B). The
levels of miR-142-3p were significantly increased in
the Hepa1-6 cells incubated with the MVs of the
propofol-treated TAMs (Figure 3C). Furthermore, the
migration of Hepa1-6 cells was significantly decreased
(Figure 3D).
We further analyzed the effect of propofol on the
expression of miR-142-3p in macrophages and MVs
in vitro. Briefly, the Raw 264.7 cells were exposed to
different concentrations of propofol for 24 h. The
levels of miR-142-3p were dose-dependently elevated
in both macrophages and MVs (Figure 3E and 3F).
The incubation with the MVs from the propofol-
treated Raw 264.7 cells significantly inhibited theFigure 4 MVs collected from the plasma of tumor-bearing mice inject
mice were treated with MVs collected from the plasma of tumor-bearing mic
was detected. (B) Tumor sizes and (C) tumor weights were measured in tumo
differences from control.migration of Hepa1-6 cells (Figure 3G). Overexpres-
sion of RAC1 in Hepa1-6 cells reversed the effect of these
MVs on the migration of the HCC cells (Figure 3H). How-
ever, the expression of miR-142-3p was not up-regulated
when the Hepa1-6 cells were directly treated with propo-
fol (Figure 3I).
MVs in the plasma of the propofol-injected mice
enhanced anti-HCC activity in vivo
To further explore the role of MVs in anti-HCC, we col-
lected MVs from the plasma of the tumor-bearing mice
injected with or without propofol (20 mg/kg). Plasma
miR-142-3p levels were increased in the tumor-bearing
mice treated with the MVs of the propofol-injected mice
(Figure 4A). Tumor growth was also significantly inhib-
ited in these mice (Figure 4B and 4C). These results sug-
gest that secreted miR-142-3p may be involved in the
anti-HCC effect of propofol.
miR-142-3p was involved in the anti-tumor activity
of propofol
To further explore the role of miR-142-3p in MVs from
macrophages, we treated Raw 264.7 cells with an miR-
142-3p inhibitor. The results of real-time PCR showed
that the miR-142-3p inhibitor profoundly reduced the
levels of miR-142-3p in the Raw 264.7 cells and MVs
(Figure 5A and 5B). The MVs from the propofol-treated
cells (5 μg/ml) that were transfected with the miR-142-
3p inhibitor significantly decreased miR-142-3p levels ined with propofol enhance anti-HCC in vivo. The tumor-bearing
e injected with or without propofol. (A) The level of plasma miR-142-3p
r-bearing mice injected with plasma MVs. *P < 0.05, indicate significant
Figure 5 miR-142-3p was involved in the effect of propofol on anti-tumor activity. (A) The expression of miR-142-3p was detected in Raw
264.7 cells transfected with miR-142-3p inhibitor. (B) The expression of miR-142-3p was measured in MVs from Raw 264.7 cells transfected with
miR-142-3p inhibitor. The expression of miR-142-3p (C) and the invasion ability (D) were detected in Hepa1-6 cells treated with MVs from Raw
264.7 cells transfected with Nc or miR-142-3p inhibitor. (E) Tumor sizes and (F) tumor weights were measured in tumor-bearing mice injected
with Nc or miR-142-3p inhibitor. *P < 0.05, **P < 0.01 indicate significant differences from control group. #P < 0.05, ##P < 0.01 indicate significant
differences from propofol group.
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(Figure 5C and 5D).
After an intratumoral injection of the miR-142-3p
inhibitor, the size of the tumors in the tumor-bearing
mice slightly increased. However, the inhibition of tumor
growth by propofol (20 mg/kg) was restored by the
miR-142-3p inhibitor (Figure 5E and 5F). These results
indicate that miR-142-3p was involved in the anti-HCC
activity of propofol.Discussion
This is the first study describing the anti-HCC effect of
propofol in vivo. We demonstrated that propofol inhib-
ited tumor growth in tumor-bearing mice by activation
of macrophages. Propofol stimulated TAMs to secrete
MVs and deliver miR-142-3p to HCC cells, resulting in
the inhibition of HCC cell invasion. In addition, MVs
collected from the plasma of the tumor-bearing mice
injected with propofol suppressed tumor growth. More
Zhang et al. Journal of Translational Medicine 2014, 12:279 Page 8 of 9
http://www.translational-medicine.com/content/12/1/279importantly, down-regulation of miR-142-3p expression
reversed the effect of propofol on HCC cell migration.
Tumor-associated macrophages (TAMs) promote tumor
cell proliferation, invasion, and angiogenesis [26]. In this
study, we first demonstrated that macrophages may serve
as treatment targets of propofol. The deletion of macro-
phage activation using clodrolip abolished the anti-HCC
activity of a moderate dose of propofol (20 mg/kg). The
combination of a high dose of propofol (50 mg/kg) and
clodrolip was less than twice as effective as either alone
in inhibiting tumor growth. Our previous study also
showed that propofol directly induced apoptosis and
inhibited the invasiveness of HCC cells [13,14]. There-
fore, a low or moderate dosage of propofol exerts anti-
HCC activity mainly through macrophages, whereas a
high dose of propofol inhibits tumor growth via macro-
phages and HCC cells.
Within the tumor microenvironment, MVs mediate
communication between macrophages and tumor cells
[27,28]. We demonstrated that propofol exerted anti-
HCC activity by modulating the expression of miR-
142-3p in macrophage-derived MVs. First, miR-142-3p
plasma levels were increased in the MVs of the propofol-
injected mice, and this significantly inhibited tumor
growth. Second, the administration of MVs from propofol-
treated macrophages increased miR-142-3p levels in HCC
cells, but propofol itself did not up-regulate miR-142-3p
expression in HCC cells. Third, MVs shed from propofol-
injected TAMs were enriched in miR-142-3p. By depleting
miR-142-3p expression, we showed that the miR-142-
3p in the MVs accounted for the anti-HCC effect of
propofol. We demonstrated that the miR-142-3p in the
MVs was taken up by HCC cells and subsequently inhib-
ited cell migration.
A previous study confirmed that miR-142-3p sup-
pressed migration and invasion of HCC cells through
down-regulation of RAC1 [19]. As a target of miR-
142-3p, RAC1 plays a key role in tumor cell growth,
migration and invasion [29,30]. We demonstrated that
the expression of RAC1 was significantly decreased
in HCC cells following incubation with TAMs from
propofol–treated HCC tissue. More importantly, overex-
pression of RAC1 in HCC cells could abolish the effect of
MVs on the migration of tumor cells.
Conclusions
In summary, we demonstrated that propofol effectively
inhibited tumor growth in vivo. We showed that propofol
stimulated miR-142-3p shuttling from macrophages to
HCC cells and that miR-142-3p down-regulated RAC1 ex-
pression, thus, inhibiting HCC cell migration and invasion.
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